In a significant development for the life sciences sector, Schroders Capital Global Innovation Trust plc has announced a strategic investment of $1.6 million (£1.3 million) in Neurona Therapeutics, a leading US-based clinical-stage cell therapy company. This investment was part of Neurona’s Series E financing round, which successfully raised $120 million. The round was co-led by […]
California-based gene therapy company 4D Molecular Therapeutics (4DMT), which is focused on adeno-associated virus (AAV) gene therapy vector discovery and product development, has raised $70 million through a Series C financing round. The Series C financing round was led by Viking Global Investors. It also saw participation from new investors such as Amzak Health, Casdin […]
BridgeBio Pharma, a leading clinical-stage biopharma company specialising in treatments for genetic diseases, has raised $299.2 million in a new funding round. The California-based firm plans to use the funds to support its drug development programmes and enhance its research and development (R&D) efforts, specifically focusing on expanding treatments for patients with unmet needs. KKR […]
California-based 4D Molecular Therapeutics (4DMT), specializing in adeno-associated virus (AAV) gene therapy vector discovery and product development, has successfully raised $90 million through a Series B financing round. The round was led by Viking Global Investors, with participation from notable investors including ArrowMark Partners, Janus Henderson Investors, The Biotechnology Value Fund, MiraeAsset Financial Group, Pfizer […]